MLMing Li

Ming Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ming Li has a total of 3 co-authors. Here are the top co-authors by number of shared publications:

  • Zhibo Li

    Department of Cardiovascular Internal Medicine the Second Hospital of Jilin University Changchun China

    1 shared publication
  • Zhuo Zhao

    Department of Cardiovascular Internal Medicine the Second Hospital of Jilin University Changchun China

    1 shared publication
  • Ziyuan Guo

    Department of Cardiovascular Internal Medicine the Second Hospital of Jilin University Changchun China

    1 shared publication

Latest Publications

  • Oncovirus‐Driven Endothelial Plasticity: Endothelial‐to‐Mesenchymal Transition as a Hijacked Pathway in Oncoviral Cardiovascular Pathogenesis

    by Ming Li, Zhibo Li, Zhuo Zhao, Ziyuan Guo

    Oncoviruses utilise various molecular strategies to modulate host cells and induce microenvironments that favour viral persistence, immune evasion, and disease progression. Endothelial‐to‐mesenchymal transition (EndMT) has recently emerged as a critical, yet underrecognized, pathway hijacked by oncoviral pathogens to modulate endothelial plasticity within the cardiovascular system. Accumulating evidence indicates that Oncogenic and non‐oncogenic viruses, including Kaposi's sarcoma–associated herpesvirus (KSHV/HHV‐8), severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), human immunodeficiency virus (HIV), and other endothelial‐tropic viruses, directly manipulate host signalling networks, such as TGF‐β, Wnt/β‐catenin, Notch, and NF‐κB, to induce partial or complete EndMT. This virus‐driven EndMT contributes to vascular remodelling, chronic inflammation, aberrant angiogenesis, and the development of oncoviral‐associated cardiovascular pathology and vascular tumours. The present review integrates current virological and mechanistic insights into EndMT as a hijacked host process, highlighting its role at the virus–host interface and discussing emerging antiviral and pathway‐targeted strategies aimed at limiting oncovirus‐mediated endothelial dysfunction.